Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any autosomal dominant non-syndromic intellectual disability in which the cause of the disease is a mutation in the COL4A3BP gene.
Features include always present findings: Intellectual disability and Global developmental delay; and common findings: Bilateral tonic-clonic seizure, Epicanthus, Upslanted palpebral fissure, and Hearing loss (hearing impairment) and others.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 5 | Bilateral tonic-clonic seizure, Cerebral visual impairment, Intellectual disability |
Arms and legs | 2 | Short foot, 2-3 toe syndactyly |
Eyes | 2 | Cerebral visual impairment, Bilateral ptosis |
Muscles | 2 | Axial hypotonia, Myopathic facies |
Ears | 1 | Hearing loss (hearing impairment) |
Head and neck | 1 | Secondary microcephaly |
CERT1 encodes ceramide transporter 1 (624 aa). Shelters ceramides inside its steroidogenic acute regulatory lipid transfer (START) domain and mediates their intracellular trafficking in a non-vesicular manner from the endoplasmic reticulum to the Golgi apparatus for conversion to sphingomyelin. Highest expression in Brain Cerebellar Hemisphere (36.9 TPM) and Thyroid (35.2 TPM).
Intellectual disability, autosomal dominant 34 is associated with mutations in the CERT1 gene on chromosome 5.
The CERT1 protein participates in CERT1-2 transfers CERA from the ER membrane to the Golgi membrane and Sphingolipid de novo biosynthesis pathways.
CERT1 is classified as a druggable target (Kinase category) with score 0.0.
Genetic testing for CERT1 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 2 always present features, 23 common features.
No clinical trials have been registered for intellectual disability, autosomal dominant 34.
8 publications have been identified in PubMed for intellectual disability, autosomal dominant 34. Research spans Case Report / Case Series (50%), Basic Science / Preclinical (25%), and Review / Meta-Analysis (13%).
Musante L (2026). [PMID: 41709284](https://pubmed.ncbi.nlm.nih.gov/41709284/). *Genome Med*. [Basic Science / Preclinical]
Sokolova T (2026). [PMID: 41718288](https://pubmed.ncbi.nlm.nih.gov/41718288/). *Reports (MDPI)*. [Case Report / Case Series]
Pan X (2026). [PMID: 41764152](https://pubmed.ncbi.nlm.nih.gov/41764152/). *Journal of molecular medicine (Berlin, Germany)*. [Epidemiology / Natural History]
Dubot P (2025). [PMID: 38706107](https://pubmed.ncbi.nlm.nih.gov/38706107/). *J Inherit Metab Dis*. [Review / Meta-Analysis]
Abenza-Abildúa MJ (2025). [PMID: 40285998](https://pubmed.ncbi.nlm.nih.gov/40285998/). *Acta neurologica Belgica*. [Case Report / Case Series]
Yeter B (2025). [PMID: 40742416](https://pubmed.ncbi.nlm.nih.gov/40742416/). *European journal of pediatrics*. [Case Report / Case Series]
Zebrauskiene D (2024). [PMID: 38845031](https://pubmed.ncbi.nlm.nih.gov/38845031/). *Clinical epigenetics*. [Case Report / Case Series]
Eser M (2024). [PMID: 39722056](https://pubmed.ncbi.nlm.nih.gov/39722056/). *Molecular genetics and genomics : MGG*. [Basic Science / Preclinical]
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 1:06 PM UTC
Online Mendelian Inheritance in Man